FORGOT YOUR DETAILS?

Weekly Immune Digest

As an introduction to this new topic on our website, we will select relevant articles in the immunotherapy and immune-biomarker field, just for your interest and on a weekly basis.

If you want us to add here your achievement in these domains, just email us and Philip Beer  with one sentence on your manuscript and the correct reference.

At your service!

LUNG

COLORECTAL

PROSTATE

IMMUNOTHERAPY

 

BREAST

CLINICAL TRIALS

  • The number of cancer patients taking part in clinical trials has doubled over the last decade; hopefully this trend will continue. IQVIA Global Trends in R&D 2022
  • Only 5% of oncology drugs entering phase 1 development achieve regulatory approval; the probability of success is higher for rare tumours/subtype (16%) compared with common tumours (1%). IQVIA Global Trends in R&D 2022

BRAIN

MELANOMA

DRUG TARGETS

HAEMATOLOGICAL

CELL THERAPIES

EQUALITY

 

REGULATORY

BLADDER

TOP